Show simple item record

dc.contributor.authorChisholm, JC
dc.contributor.authorCarceller, F
dc.contributor.authorMarshall, LV
dc.date.accessioned2021-06-22T14:47:56Z
dc.date.available2021-12-22T14:47:56Z
dc.identifier.citationBritish journal of cancer, 2020, 122 (10), pp. 1425 - 1427
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4647
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/s41416-020-0770-5
dc.description.abstractThe recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children.
dc.formatPrint-Electronic
dc.format.extent1425 - 1427
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectPyrazoles
dc.subjectPyrimidines
dc.subjectOncogene Proteins, Fusion
dc.subjectAntineoplastic Agents
dc.subjectPharmaceutical Preparations
dc.subjectProtein Kinase Inhibitors
dc.subjectDrug Approval
dc.subjectPediatrics
dc.subjectAdult
dc.subjectChild
dc.titleTumour-agnostic drugs in paediatric cancers.
dc.typeOther
dcterms.dateAccepted2020-03-01
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41416-020-0770-5
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.typeOther
dc.relation.isPartOfBritish journal of cancer
pubs.issue10
pubs.notes6 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People/Sarcoma Clinical Trials in Children and Young People (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people/Sarcoma Clinical Trials in Children and Young People (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People/Sarcoma Clinical Trials in Children and Young People (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people/Sarcoma Clinical Trials in Children and Young People (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume122
pubs.embargo.terms6 months
pubs.embargo.date2021-12-22T14:47:56Z
icr.researchteamSarcoma Clinical Trials in children and young people
icr.researchteamSarcoma Clinical Trials in children and young peopleen_US
dc.contributor.icrauthorChisholm, Juliaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0